Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses (Q44592639)
Jump to navigation
Jump to search
scientific article published on October 1, 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses |
scientific article published on October 1, 2003 |
Statements
1 reference
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses (English)
1 reference
1 reference
1 reference
David Marin
1 reference
Eduardo Olavarria
1 reference
John M. Goldman
Jane F. Apperley
1 October 2003
1 reference
2702-3; author reply 2703-4
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference